Home example 2 - Pharmamarketeer

marketing

Trends in marketing & tech: relevanter & beter

Volgens keynote-speakers op Content Marketing World gaan we van snackable content naar longformsmet betekenis en staan we aan de vooravond van de doorbraak van AI en AI-gerelateerde technologieën. Balans vinden tussen...

Frankwatching.nl

1 x gelezen

overig

NICE turns down Dompe’s eye drops for rare eye condition over price concerns

NICE has announced that it has recommended against the use of Dompe’s recombinant human nerve growth factor eye drop therapy cenegermin on the NHS for the treatment of the rare eye condition neurotrophic keratitis.

Pharmafile

1 x gelezen

onderzoek

UA scientists aim to identify drug targets for rare pediatric cancer

Rhabdomyosarcoma is a rare cancer of the skeletal muscle that primarily affects pediatric patients. After diagnosis, about 3 out of 4 patients are cured with standard treatment. Survival rates drop to 17 percent if the...

News-Medical.Net

1 x gelezen

marketing

Marketing tussen feit en visie

Als marketeer ken je ze vast wel van de congressen die je met enige regelmatig bezoekt: slides met visionaire quotes die je vertellen hoe wij ons werk anders zouden moeten doen. Blauwe oceanen, de ‘crazy people’ van...

Marketingfacts.nl

1 x gelezen

technologie

De stem van de patiënt

De stem van de patiënt (intreerede Maarten van der Elst) Willen we de zorg betaalbaar en bereikbaar houden dan zullen we technologie hard nodig hebben. De invoer daarvan moet dan wel gebeuren op een manier die recht...

Medicalfacts

1 x gelezen

onderzoek

Aptamer Therapeutics collaborates with Cancer Research UK for drug development program

Following the successful awarding of a CRUK Biotherapeutic Drug Discovery Project Award, Aptamer Therapeutics Limited, part of Aptamer Group, is pleased to announce a new collaboration with Dan Wiseman and the Oglesby...

News-Medical.Net

1 x gelezen

overig

INC Research and inVentiv merge to form Syneos Health

With the advent of the new year, INC Research and inVentiv Health have announced they are to merge operations under a new brand identity: Syneos Health.

Pharmafile

1 x gelezen

overig

Shire dropped oncology unit for $2.4bn, unbalancing Takeda deal

Shire has announced that it has entered a definitive agreement for French drugmaker Servier to take on its oncology business.

Pharmafile

1 x gelezen

wet- en regelgeving

FDA issues EUA for third COVID-19 vaccine

FDA Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the third vaccine for the prevention of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome...

News-Medical.Net

1 x gelezen

onderzoek

AbbVie terminates Phase 3 brain cancer study after Depatux-M shows no benefit

AbbVie has terminated a Phase 3 study of the efficacy of Depatux-M (depatuxizumab mafodotin) in the treatment of newly diagnosed glioblastoma (GBM) in patients whose tumours have epidermal growth factor receptor (EGFR)...

InPharm.com

1 x gelezen

Latest articles

Trends in marketing & tech: relevanter & beter

NICE turns down Dompe’s eye drops for rare eye condition over price concerns

UA scientists aim to identify drug targets for rare pediatric cancer

Marketing tussen feit en visie

De stem van de patiënt

Aptamer Therapeutics collaborates with Cancer Research UK for drug development program

INC Research and inVentiv merge to form Syneos Health

Shire dropped oncology unit for $2.4bn, unbalancing Takeda deal

FDA issues EUA for third COVID-19 vaccine

AbbVie terminates Phase 3 brain cancer study after Depatux-M shows no benefit

Wekelijkse highlights per e-mail

Algemene informatie